PREVENTION OF GENITAL HERPES SIMPLEX INFECTION

完成了十多年的生殖器抗病毒治疗工作 关于疱疹，我们转向了疾病预防的研究。我们完成了一个公开赛 一种新的重组单纯疱疹病毒2型糖蛋白D的2年期1期评估 24名成人接种明矾疫苗，其中一些人之前有或没有之前的HSV-1和/或2 感染。分别在0、1、2和12天接种30微克或100微克的疫苗 几个月，局部或全身反应最小。这个 疫苗诱导细胞免疫应答中优良的一抗 并显著增强了先前存在的体液和细胞反应。我们 研究了来自以前未感染的受试者的抗体和T细胞 表明抗体和细胞识别的GD2表位 与生殖器疱疹患者的情况相对应。在此基础上 优秀反应：我们招募了40名复发性生殖器疱疹患者 进入一项安慰剂对照疫苗试验 华盛顿大学。其目标是确定是否已增强 免疫导致较少的复发。这项研究是最近进行的 已完成，数据正在检查中。我们也开始筹划 GD2和GB2在强效新佐剂存在下的进一步研究 MF59。

Having completed over a decade of work on antiviral treatment of genital herpes, we turned to studies of disease prevention. We completed an open 2 year phase 1 assessment of a new recombinant HSV-2 glycoprotein D vaccine in alum in 24 adults, some with and without prior HSV-1 and/or 2 infection. Vaccinations of 30 ug or 100 ug were given at 0, 1, 2, and 12 months and were associated with minimal local or systemic reactions. The vaccine induced excellent primary antibody in cellular immune responses and augmented preexisting humoral and cellular responses signicantly. We studied antibody and T cells from previously uninfected subjects and showed that the gD2 epitopes that the antibody and cells recognize correspond to those in genital herpes patients. On the basis of these excellent responses we enrolled 40 patients with recurrent gential herpes into a placebo-controlled vaccine trial in collaboration with the University of Washington. The goal is to determine whether boosted immunity leads to less frequent recurrences. The study was recently completed and the data are being examined. We have also begun to plan for further studies using gD2 and gB2 in the presence of potent new aadjuvant MF59.